Form 4: CG Oncology Director Granted Stock Options
Insider Transaction Report
CG Oncology director Christina Rossi received 20,889 stock options with a vesting schedule commencing November 24, 2025.
Summary
- Christina Rossi, a Director at CG Oncology, Inc. (CGON), was granted 20,889 stock options.
- The options have an exercise price of $43.56 per share.
- The vesting commencement date for these options is November 24, 2025.
- The options will vest monthly at a rate of 1/36th of the total shares, subject to continuous service.
- The expiration date for these options is November 23, 2035.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 7
Explanation: The grant of stock options to a director is generally a positive event, aligning management incentives with shareholder value. It's a standard compensation practice and indicates continued commitment.
Positives
- The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
- The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan designed to avoid accusations of insider trading.
Future Outlook
The options will vest monthly over a 36-month period starting November 24, 2025, contingent on the director's continuous service to CG Oncology, Inc.
Industry Context
This is a routine insider compensation event, common across publicly traded companies, particularly in the biotechnology sector, to attract and retain executive talent and align their interests with long-term shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 11/24/2025 | Enhances transparency and provides a legal defense against insider trading allegations by establishing a pre-arranged trading schedule. |
Stakeholder Impact
- Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders through motivated leadership.
- Employees: Standard compensation practices for directors can influence overall compensation philosophy within the company.
Next Steps
- The options will begin vesting monthly from November 24, 2025, over the next 36 months.
Key Dates
| Date | Description |
|---|---|
| 11/24/2025 | Transaction date and vesting commencement date for the stock options. |
| 11/26/2025 | Date the Form 4 was signed and filed. |
| 11/23/2035 | Expiration date of the stock options. |
Keywords
CG Oncology, CGON, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.